Fred Eshelman

Fredric N.
Eshelman founded PPD, Inc. in 1985, Pharmaceutical Product Development LLC in 1985, where he worked as Executive Chairman from 2009 to 2011, and Incyclix Bio LLC in 2020, where he is working as Chairman from 2020.
Dr. Eshelman also founded Eshelman Ventures LLC.
Dr. Eshelman also currently works at Innocrin Pharmaceuticals Holdings LLC, as Chief Executive Officer & Director, Innocrin Pharmaceuticals, Inc., as Chief Executive Officer & Director, Cellective BioTherapy, Inc., as Chairman, Dignify Therapeutics LLC, as Director, Aton Pharma, Inc., as Director, Aero MD, as Director, North Carolina School of Science & Mathematics, as Member-Governors Board, and the University of North Carolina System, as Member-Governors Board.
Dr. Eshelman also formerly worked at The Medicines Co., as Executive Chairman from 2017 to 2020, Furiex Pharmaceuticals, Inc., as Chairman from 2011 to 2014, Hyperion DeFi, Inc., as Chairman from 2018 to 2022, Aravive, Inc., as Executive Chairman from 2022 to 2024, XORI Corp., as Director, Neoantigenics, Inc., as Director, Jumo Health, Inc., as Director, The North Carolina Biotechnology Center, as Director, Glaxo, Inc., as Director & Senior Vice President-Development from 1989 to 1990, Bausch Health Cos., Inc., as Independent Director from 2015 to 2018, G1 Therapeutics, Inc., as Independent Director from 2015 to 2021, Meryx, Inc., as Director, Asepticys LLC, as Director, Amplitude Healthcare Acquisition Corp., as Independent Director, Kinnate Biopharma, Inc., as Director, The University of North Carolina at Wilmington, as Trustee, North Carolina General Assembly (North Carolina), as Member-Governors Board, Accelerator Services Corp, as Board Member, Boehringer Mannheim Pharmaceuticals Corp., as Principal, and Harvard Business School, as Owner & President-Management Program.
Dr. Eshelman received his doctorate degree from the University of Cincinnati (Ohio) and undergraduate degree from The University of North Carolina at Chapel Hill.